Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.9 GBX | +3.45% | +4.65% | +14.21% |
Apr. 05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
Apr. 05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Sales 2024 * | 2.24M 2.8M | Sales 2025 * | 3.28M 4.09M | Capitalization | 7.14M 8.91M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.25M | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.55 x |
Net cash position 2024 * | 3.66M 4.57M | Net cash position 2025 * | 2.95M 3.68M | EV / Sales 2025 * | 1.28 x |
P/E ratio 2024 * |
-2.65
x | P/E ratio 2025 * |
-7.67
x | Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.93% |
Latest transcript on RUA Life Sciences plc
1 day | -2.17% | ||
1 week | +4.65% | ||
Current month | -2.17% | ||
1 month | -6.25% | ||
3 months | +0.90% | ||
6 months | -10.00% | ||
Current year | +14.21% |
Managers | Title | Age | Since |
---|---|---|---|
Lachlan Smith
DFI | Director of Finance/CFO | - | 21-11-30 |
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John McKenna
BRD | Director/Board Member | 71 | 16-10-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John Louis Ely
BRD | Director/Board Member | 73 | - |
Director/Board Member | 57 | 21-01-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 11.9 | +3.45% | 77 874 |
24-05-07 | 11.5 | +1.10% | 254,532 |
24-05-03 | 11.38 | +2.25% | 90,931 |
24-05-02 | 11.12 | +3.49% | 645,672 |
24-05-01 | 10.75 | -6.52% | 384,043 |
Delayed Quote London S.E., May 08, 2024 at 08:41 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.21% | 8.95M | |
+7.93% | 219B | |
+7.53% | 184B | |
+15.20% | 138B | |
-1.14% | 62.54B | |
+7.23% | 52.22B | |
+12.58% | 51.73B | |
+1.61% | 41.4B | |
+5.32% | 37.17B | |
+25.66% | 31.76B |
- Stock Market
- Equities
- AOR Stock